EligibleTrials

Safety and Durability of Sirolimus for Treatment of LAM

Recruiting · NCT02432560 · Observational (researchers observe without assigning treatment)

View the official record on ClinicalTrials.gov →
Lung cancer

Interventions studied

EverolimusSirolimus

What this trial is about

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Who can take part

Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

20 locations listed across 18 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.